Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

(OP:ESAIY)

7.340 +0.020 (+0.27%)
Streaming Delayed Price Updated: 3:59 PM EST, Nov 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 68,038
Open 7.340
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 7.320
Today's Range 7.300 - 7.380
52wk Range 5.940 - 9.270
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
FDA Approves Biogen, Eisai's Highly Anticipated Alzheimer's Treatment
This could put pressure on Eli Lilly, which sells a competing drug called Kisunla. 
Via Investor's Business Daily
Biogen Easily Tops Earnings Forecasts As Leqembi, Skyclarys Sales Soar
The company beat first-quarter expectations, partly thanks to strong sales of its rare disease drugs. 
Via Investor's Business Daily
Topics Earnings

Performance

YTD
+8.6%
+8.6%
1 Month
-10.0%
-10.0%
3 Month
+0.4%
+0.4%
6 Month
-1.2%
-1.2%
1 Year
-12.1%
-12.1%

More News

Read More
Trump Wants RFK Jr. To 'Go Wild' On Health Care. What This Means For Biotech Stocks.
Via Investor's Business Daily
Topics Government
Why Investors Might Hammer Biogen Despite Its Earnings Beat
Via Investor's Business Daily
Merck/Eisai's Keytruda Plus Lenvima Regime Shows Mixed Data In Esophagus Cancer Study
Via Benzinga
Week In Review: Multitude Out-Licenses Tissue Factor ADC To Adcendo In $1 Billion Deal
Via Talk Markets
Biogen's Alzheimer's Drug Secures UK Approval, But An Independent Agency Does Not Recommend Reimbursement
Via Benzinga
Week In Review: Eisai Enters $1.5 Billion Molecular Glues Pact With SEED
Via Talk Markets
Biogen Stock Tumbles After European Regulators Unexpectedly Reject Alzheimer's Drug
Via Investor's Business Daily
The 3 Best Neuroscience Biotech Stocks to Buy Now
Via InvestorPlace
Week In Review: Samsung Biologics Signs $1 Billion Manufacturing Contract With US Biopharma
Via Talk Markets
3 Highly Rated Biotech Stocks for Your July Buy List
Via InvestorPlace
Eli Lilly's Alzheimer's Therapy's Broad Label Reflects Regulatory Confidence in Anti-Amyloid Antibodies: Analyst
Via Benzinga
Eli Lilly Snags Long-Awaited Alzheimer's Drug Approval, Rivaling Biogen, Eisai
Via Investor's Business Daily
Eli Lilly's Donanemab Gains Favorable FDA Advisory Verdict, Boosting Stock Potential, Says BofA Analyst
Via Benzinga
Eli Lilly Drags Alzheimer's Stocks Prothena, Eisai Lower Despite FDA Win
Via Investor's Business Daily
Eli Lilly Rises Again, As FDA Panel Mulls Biogen-Rivaling Alzheimer's Drug
Via Investor's Business Daily
The 3 Most Undervalued Pharma Stocks to Buy in June 2024
Via InvestorPlace
Topics Economy
Biogen Stock Continues Its 20% Sprint On A Twist In Alzheimer's Treatment
Via Investor's Business Daily
Two Notable Biogen Drugs Walloped Sales Forecasts. Will It Be Enough To Reverse Biogen Stock's Decline?
Via Investor's Business Daily
Topics Earnings
3 Stocks Wall Street Is Ignoring (But You Shouldn’t): April Edition
Via InvestorPlace
Race To Treat Alzheimer's Disease Is Heating Up Despite Eli Lilly's Setback
Via Investor's Business Daily
3 Millionaire-Maker Stocks to Buy While the Gettin’ Is Good
Via InvestorPlace
Week In Review: I-Mab Morphs Into US-Only Company; Sells China Assets For $80 Million
Via Talk Markets
Brain Disease Cures: 3 Neuroscience Stocks Targeting Revolutionary Breakthroughs
Via InvestorPlace

Frequently Asked Questions

Is ESAIY publicly traded?
Yes, ESAIY is publicly traded.
What exchange does ESAIY trade on?
ESAIY trades on the OTC Traded
What is the ticker symbol for ESAIY?
The ticker symbol for ESAIY is ESAIY on the OTC Traded
What is the current price of ESAIY?
The current price of ESAIY is 7.340
When was ESAIY last traded?
The last trade of ESAIY was at 11/03/25 03:59 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.